Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 4Withdrawn 2Terminated 2Completed 2Suspended 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 8Lymphoma, Mantle-Cell 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, Non-Hodgkin 4Hodgkin Disease 4Lymphoma, T-Cell 3Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Biphenotypic, Acute 2Hematologic Neoplasms 2Waldenstrom Macroglobulinemia 1Plasmablastic Lymphoma 1Neoplasm, Residual 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, Primary Effusion 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Histiocytosis, Langerhans-Cell 1HIV Infections 1Composite Lymphoma 1Burkitt Lymphoma 1

Interventions

Rituximab 47Cyclophosphamide 26fludarabine 13ibrutinib 12Doxorubicin 11Vincristine 10Etoposide 10Cytarabine 10Prednisone 9Bortezomib 9pembrolizumab 7fludarabine phosphate 6Lenalidomide 6Inotuzumab Ozogamicin 6obinutuzumab 5Mycophenolic Acid 5Melphalan 5Carmustine 5tositumomab I-131 4ibritumomab tiuxetan 4Tacrolimus 4Prednisolone 4Methotrexate 4Gemcitabine 4Bendamustine Hydrochloride 4Antilymphocyte Serum 4tocilizumab 3tazemetostat 3Whole-Body Irradiation 3Vorinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lymphoma, B-Cell × CT-P10 × Clear all
NCT01701986 2025-02-28

Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Completed
64 enrolled 13 charts
Lymphoid

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, T-Cell

NCT01729806 2018-04-11

Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
32 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡